Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model

Open link

Publication date

December 2012

DOI

10.1186/1472-6963-12-386

Publisher

Springer Science and Business Media LLC

Journal

BMC Health Services Research

Abstract

Background: Streptococcus pneumoniae infections, which place a considerable burden on healthcare resources, can be reduced in a cost-effective manner using a 7-valent pneumococcal conjugate vaccine (PCV-7). We compare the cost effectiveness of a 13-valent PCV (PCV-13) and a 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with that of PCV-7 in Turkey. Methods: A cost-utility analysis was conducted and a decision analytical model was used to estimate the proportion of the Turkish population <10 years old that would experience 10 mutually exclusive outcomes over the course of 1 year from a perspective of a healthcare system. Model outcomes were adjusted according to the population demographics a...